Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
PURPOSE: To evaluate the efficacy and toxicity of paclitaxel administered as a 1-hour infusion on weekly basis, without interruption, to patients with metastatic breast cancer who had received prior therapy. PATIENTS AND METHODS: Thirty patients with metastatic breast cancer received sustained weekly paclitaxel therapy at an initial dose of 100 mg/m2 until disease progression. Prior therapy included adjuvant only (n=17), metastatic only (n=7), or both (n=6). Eighteen patients had received prior anthracycline therapy, 12 of whom had demonstrated progression of disease within 12 months of it. All patients were assessable for efficacy; 29 patients were assessable for toxicity. Pharmacokinetic studies of paclitaxel were also performed. RESULTS: A total of 469 weekly paclitaxel infusions were administered to 30 patients (median, 14 infusions/patient). The median delivered dose-intensity was 91 mg/m2/wk (range, 80 to 108). The overall response rate was 53% (95% confidence interval [CI], 34% to 72%), with 10% complete responses (CRs) and 43% partial responses (PRs). Median response duration was 7.5 months (range, 2 to 11+). Responses were observed in nine of 18 (50%) patients with prior anthracycline therapy, including six of 12 (50%) with disease progression on anthracycline within 1 year (three of four within 6 months). Therapy was well tolerated and remarkable for a lack of overall and cumulative myelosuppression. Grade 3/4 neutropenia occurred in four patients; febrile neutropenia was not observed. Peripheral neuropathy prohibited dose escalation above 100 mg/m2, and grade 3 neuropathy was observed in two of 21 patients at < or = 100 mg/m2. CONCLUSION: Weekly paclitaxel therapy is active and well tolerated in patients with metastatic breast cancer. Weekly therapy should be considered as a current clinical option for these patients and should be incorporated into future comparative clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Baselga, J. M., Norton, L., Albanell, J., Kim, Y. M., & Mendelsohn, J. M. (1998) · PubMed · Cited by 996
Self-citationTHE IMPACT OF NATIONAL CANCER ACT
(1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797 · Cited by 796
Jordan, M. A., Wendell, K., Gardiner, S., Derry, W. B., Copp, H., & Wilson, L. (1996) · PubMed · Cited by 770
Klauber, N., Parangi, S., Flynn, E. A., Hamel, E., & D’Amato, R. J. (1997) · PubMed · Cited by 524
Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8.
Rahman, A., Korzekwa, K., Grogan, J., Gonzalez, F. J., & Harris, J. W. (1994) · PubMed · Cited by 430
Nabholtz, J. M., Gelmon, K., Bontenbal, M., Spielmann, M., Catimel, G., Conte, P., Klaassen, U., Namer, M., Bonneterre, J., Fumoleau, P., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1858 · Cited by 380
Slamon, D. J. (1998) · Medical Entomology and Zoology · Cited by 347
Ged, C., Rouillon, J., Pichard, L., Combalbert, J., Bressot, N., Bories, P., Michel, H., Beaune, P., & Maurel, P. (1989) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1989.tb03516.x · Cited by 333
Huizing, M. T., Keung, A. C., Rosing, H., van der Kuij, V, ten Bokkel Huinink, W. W., Mandjes, I. M., Dubbelman, A. C., Pinedo, H. M., & Beijnen, J. H. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2127 · Cited by 308
Harris, J. W., Rahman, A., Kim, B.-R., Guengerich, F. P., & Collins, J. M. (1994) · PubMed · Cited by 283
Fennelly, D., Aghajanian, C., Shapiro, F., O'Flaherty, C., McKenzie, M., O'Connor, C., Tong, W., Norton, L., & Spriggs, D. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.187 · Cited by 242
Self-citationReichman, B. S., Seidman, A. D., Crown, J. P., Heelan, R., Hakes, T. B., Lebwohl, D. E., Gilewski, T. A., Surbone, A., Currie, V, & Hudis, C. A. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1943 · Cited by 237
Self-citationWilson, W. H., Berg, S. L., Bryant, G., Wittes, R. E., Bates, S., Fojo, A., Steinberg, S. M., Goldspiel, B. R., Herdt, J., & O'Shaughnessy, J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.8.1621 · Cited by 216
Seidman, A. D., Reichman, B. S., Crown, J. P., Yao, T. J., Currie, V, Hakes, T. B., Hudis, C. A., Gilewski, T. A., Baselga, J., & Forsythe, P. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.5.1152 · Cited by 205
Self-citationSeidman, A. D., Tiersten, A., Hudis, C., Gollub, M., Barrett, S., Yao, T. J., Lepore, J., Gilewski, T., Currie, V, & Crown, J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.10.2575 · Cited by 203
Self-citationGianni, L., Munzone, E., Capri, G., Villani, F., Spreafico, C., Tarenzi, E., Fulfaro, F., Caraceni, A. T., Martini, C., Laffranchi, A., et al. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.15.1169 · Cited by 144
Ohtsu, T., Sasaki, Y., Tamura, T., et al. (1995) · PubMed · Cited by 143
A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines
Fountzilas, G., Athanassiades, A., Giannakakis, T., Bafaloukos, D. I., Karakousis, K., Dombros, N., Kosmidis, P., & Skarlos, D. V. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00398-3 · Cited by 53
Dorr, R. T. (1997) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1997.tb03811.x · Cited by 36
Cited by
Seidman, A. D., Berry, D., Cirrincione, C., Harris, L., Muss, H., Marcom, P. K., Gipson, G., Burstein, H., Lake, D., Shapiro, C. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6699 · Cited by 594
Self-citationPaclitaxel’s Mechanistic and Clinical Effects on Breast Cancer
Abu Samaan, T. M., Samec, M., Liskova, A., Kubatka, P., & Büsselberg, D. (2019) · Biomolecules · doi:10.3390/biom9120789 · Cited by 569
Seidman, A. D., Fornier, M. N., Esteva, F. J., Tan, L., Kaptain, S., Bach, A., Panageas, K. S., Arroyo, C., Valero, V., Currie, V., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2587 · Cited by 547
Self-citationPaclitaxel: a review of adverse toxicities and novel delivery strategies
Marupudi, N. I., Han, J. E., Li, K. W., Renard, V. M., Tyler, B. M., & Brem, H. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.5.609 · Cited by 510
Peripheral Neuropathy Induced by Microtubule-Stabilizing Agents
Lee, J. J., & Swain, S. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0543 · Cited by 472
Metadata
- Authors
- Seidman, A. D., Hudis, C. A., Albanell, J., Albanel, J., Tong, W., Tepler, I., Currie, V, Moynahan, M. E., Theodoulou, M., Gollub, M., Baselga, J., & Norton, L.
- Venue
- Journal of Clinical Oncology
- Published
- 1998-10
- Volume
- 16
- Issue
- 10
- Pages
- 3353-3361
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1946819517
- Cited by
- 378
- References
- 19
- FWCI
- 8.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.